Location Directory

Clinical trials in Austin, Texas

This page shows live ClinicalTrials.gov search results for Austin, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2579

Shown on this page

Local exact-city summaries

2579

Based on exact city/state matches in the local index.

Local exact-city recruiting

505

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Austin, Texas. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 2,579 matching trials in Austin, TX.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Austin, TX. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Diabetes Mellitus, Type 2 53 Obesity 50 Breast Cancer 48 Schizophrenia 43 Diabetic Macular Edema 41 Rheumatoid Arthritis 40

Top sponsors in local exact-city summaries

Pfizer 106 Children's Oncology Group 102 Eli Lilly and Company 87 National Cancer Institute (NCI) 83 University of Texas at Austin 80 AbbVie 76

Top therapies in local exact-city summaries

Cyclophosphamide 65 Carboplatin 59 Paclitaxel 42 Pembrolizumab 39 Cisplatin 34 Methotrexate 34

Indexed official records

Open in full search

Conditions: Diabetic Retinopathy
Interventions: Artificial Tears, Sham, Surabgene Lomparvovec, Topical Steroid; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 2
States / cities: Oak Forest, Illinois • Austin, Texas

Conditions: Castration-resistant Prostate Cancer (CRPC), ER+, HER 2- Breast Cancer, Microsatellite Stable (MSS) Colorectal Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Interventions: Fulvestrant injection, IDE574; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: East Brunswick, New Jersey • Lake Success, New York • Austin, Texas + 6 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Aflibercept, Ixo-vec; Drug · Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 38 more

Conditions: Post Traumatic Stress Disorder
Interventions: Placebo, TSND-201; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 152
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Doxorubicin, Paclitaxel, Puxitatug Samrotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 66
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more

Conditions: Chronic Low Back Pain (CLBP), Obesity, Overweight
Interventions: Placebo, Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more

Conditions: FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC
Interventions: TYRA-300 50mg, TYRA-300 60mg, TYRA-300 Dose TBD; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more

Conditions: Castration-resistant Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions: DCC-2812; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 2 more

Conditions: Follicular Lymphoma
Interventions: Bendamustine, Cyclophosphamide, Doxorubicin, Golcadomide, Lenalidomide, Prednisone/Prednisolone, Rituximab, Vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 31
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more

Conditions: Large B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel; Drug · Device · Genetic
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 47 more

Clinical trials in Austin, Texas

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study of COYA 302 for the Treatment of ALS

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL